

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Poverty and Cardiovascular Diseases in Sub-Saharan Africa

Julius Chacha Mwita and Brian Godman

Abstract

There is a rise in cardiovascular diseases (CVDs) in sub-Saharan Africa (SSA). Even though SSA is home to 14% world's inhabitants, it is home to more than half of the global poor. The objective of this chapter is to evaluate the interconnection between CVD and poverty in SSA. We found that the relationship between poverty and CVD is bidirectional. The intersection between poverty and CVD cuts through primordial, primary prevention and secondary prevention interventions. In the context of poverty in SSA, CVD prevention is a challenge due to competing demands to address the never conquered infectious diseases exacerbated by the current COVID-19 pandemic. With a weak healthcare system and out of pocket payment for the costs of CVD care, a significant proportion of individuals with CVD and their households are consequently impoverished. Besides, CVD affects a younger and productive population in SSA than in the rest of the world. Thus, CVD-related loss of productivity progressively pushes an additional number of individuals into poverty, requiring urgent attention.

Keywords: cardiovascular diseases, medicines, poverty, sub-Saharan Africa

1. Introduction

Cardiovascular diseases (CVDs) include coronary heart disease, cerebrovascular diseases, peripheral arterial disease, rheumatic and congenital heart disease, and deep vein thrombosis [1]. Except for coronary heart disease on the rise in urban areas, hypertension, stroke, cardiomyopathies, and rheumatic heart disease are the most common CVDs across sub-Saharan Africa (SSA) [2, 3]. CVDs account for 30% of global deaths, and about 80% of them occurring in low- and middle-income countries (LMICs), including SSA [2, 4]. By 2030, projections show that CVD alone will cause more SSA deaths than infectious diseases, maternal and perinatal conditions, and nutritional disorders combined [5]. Consequently, an increasing priority area for future activities. The rising burden of CVD in SSA is due to increasing population exposure to various modifiable risk factors that account for at least three-quarters of all the CVDs [3]. The risk factors include unhealthy diets, physical inactivity, hypertension, obesity, diabetes, dyslipidaemia, and tobacco use [4]. Given the poverty and multiple competing health priorities across SSA, similar to several other LMICs, both prevention and treatment of CVDs get less attention [3]. With the high patient co-payments in many SSA countries, CVDs impose a significant health and economic burden on individuals and families in the region than in higher-income countries [6]. Above and beyond, poverty may contribute to an increased burden of CVD by its effect on several social and cultural factors

responsible for the increasing burden of CVD [7]. Consequently, this report looked at CVD and poverty interconnection in SSA and the implications for the future.

2. Poverty in sub-Saharan Africa

SSA is home to 14% of the 7.8 billion world's inhabitants but contributes to more than half of the global poor [8, 9]. Using the 1-dimensional measurement of poverty that focuses on income or wealth, over 40% of SSA residents live below the poverty line of \$1.90 per person per day [9]. This poverty level is far above the average poverty rate of 13% in other regions of the world [10]. While the rest of the world has observed a significant decline in extreme poverty, SSA observed a rise in the number of people living in extreme poverty from 278 million in 1990 to 413 million in 2015 [9, 11]. Even those who live above the \$1.90 poverty, a significant proportion of them are still very poor due to deprivations in various aspects of well-being [9, 11]. Using deprivation from education, health, and assets as multi-dimensional measures of poverty, about half (51%) of the poor population in the world lives in SSA [12]. Therefore, most sub-Saharan inhabitants lack sufficient income and basic needs, including quality health and education [12]. Most of the causes of poverty in SSA are not different from the rest of the world. They include colonialism, war and political instability, national debts, discrimination and social inequality, and vulnerability to natural disasters [13]. The impact of colonialism, the slave trade and resource extraction from SSA likely contributed in some ways to the persistent poverty in the region [14]. The existence of a significant inequality in income distribution and access to productive resources, essential social services, opportunities, markets exacerbate the already existing poverty despite the autonomy of African countries following their independence [15]. Women and children are the most affected groups with inequalities and natural catastrophic events such as drought, flooding, and frequent disease epidemics in the region [14, 15]. In these events, the already impoverished people are often displaced, lose their belongings, and remain in the vicious cycle of poverty [15].

Similarly, violent regional conflicts, forced displacement and political instability in a significant number of SSA countries interfere with safety, stability and security needed for investment and economic growth [13]. The situation is made worse by weak national institutions permissive to corruption and resource misallocation in many SSA countries [9]. As a result, these countries carry significant debts that have high-interest rates and are linked to conditions that may be unfavourable to the development of local economies [13]. The impact of HIV and AIDS is also significant as the disease affected the working-age population leading to a reduction in economic productivity [16]. In the context of all these factors, it remains unclear if the region will end poverty in all its forms by 2030 as per the Sustainable Development Goal 1 (SDG 1) [17].

3. The effect of poverty of CVD in Africa

With poverty, SSA has the lowest healthcare expenditure, the lowest life expectancy, and inadequate access to health care services, safe water, education, and sanitation facilities [18, 19]. Although poverty is among the reasons behind the region's high burden of infectious diseases such as malaria, tuberculosis and human immunodeficiency virus (HIV), it is also a reason behind the rising burden of CVDs [4]. Economic development in SSA leads to urbanisation and increased tobacco consumption, harmful alcohol use, unhealthy diets, and physical inactivity [2]. While

the wealthy population can revise their lifestyle, lack of access to both preventative and remedial health care among the poor partly explains the high burden of CVD risk factors [20, 21]. Besides poor access to healthcare services for CVD prevention and control, low education significantly affects a good understanding of the disease process and promoting a healthy lifestyle among the poor [22]. With poverty encompassing low income and consumption, poor education, health, nutrition, and other human development parameters, its effect on CVD is complex [23]. It affects different stages, ranging from primordial prevention that targets the emergence of CVD risk factors, primary prevention in the presence of CVD risk factors, and educational programmes on modifiable CVD risk factors.

Unfortunately, data on the overall burden of CVD and its association with poverty are scarce in SSA [24]. With the weak state of the health systems in many SSA countries, typical patient record systems are not sufficiently functional to support accurate morbidity and mortality data documentation [25]. Given the high burden of environmentally induced risk behaviours and limited access to good-quality and affordable health care, the CVD burden, morbidity, and mortality are disproportionately higher among the poor than the affluent population in the region [20–22, 26–28]. Only a few countries (e.g., Botswana) have a universal healthcare system that extends coverage to poor communities [28]. Besides, CVD modifiable risk factors such as hypertension, diabetes, and cholesterol disorders remain undiagnosed or untreated in a significant proportion of the poor communities in SSA [28–33]. The situation is concerning because early detection and effective management of risk factors can substantially reduce most CVD [34]. Over and above the behavioural and physiological risk factors, anger, anxiety and depression are important risk factors for CVD [35]. Poor housing, sanitation and limited access to healthcare are psychosocial stressors that may lead to anger, anxiety and depression in the poor urban sub-Saharan populations [35]. Psychosocial stressors lead to an increased behavioural risk factors for CVD such as tobacco consumption, harmful alcohol use, unhealthy diets, and physical inactivity [2]. Also, most of these populations live in overpopulated unplanned urban settlements, which are often not conducive for establishing healthy behaviours [2, 18, 19]. These communities can hardly afford healthy food and have high illiteracy levels [20, 21].

Hence, poverty leads to CVD through multiple ways that lie within and outside the health sector. Consequently, broad partnerships across various sectors are needed to achieve the 25% reduction in premature NCD mortality by 2025 (the 25 by 25 goal) in SSA [36].

Although not related to the epidemiological transition, rheumatic heart disease (RHD) is another poverty-related CVD that has remained unconquered in SSA [30, 37]. The disease is responsible for over 95% of the 492 042 global deaths per year among the young population in SSA and other impoverished communities in Oceania, South Asia, Central Asia, and the Middle East [38]. SSA (5.7 cases per 1000), the Pacific and indigenous Australia and New Zealand (3.5 cases per 1000), and south-central Asia (2.2 cases per 1000) are the regions with the highest prevalence of RHD [38]. The disease results from acute rheumatic fever (ARF) - an abnormal immunological response to Group A Streptococcal (GAS) infection of the throat [39]. Risk factors of ARF include poverty, overcrowding and reduced access to medical care, all prevalent in SSA [38, 40]. Primary prevention of ARF involves early detection and antibiotic treatment of streptococcal pharyngitis [38, 41]. Early detection and treatment of streptococcal pharyngitis require functional health care services and a community with enough health literacy and appropriate health-seeking behaviour. With rampant poverty and the absence of universal healthcare, the treatment of streptococcus pharyngitis is poorly practised in many SSA countries [42]. Consequently, RHD remains prevalent in SSA versus other countries

and an appreciable cause of premature mortality with a mean age of death as low as 25 years [43]. While medical and surgical management can reduce morbidity and mortality, poverty reduction and improvement of overall living standards are crucial in reducing the overall burden and complications of RHD [44].

4. The effect of CVD on poverty in Africa

CVDs occur approximately two decades earlier in SSA than in the rest of the world [5]. In the context of poverty and weak healthcare systems, patients with CVD in SSA have higher all-cause mortality and shorter lifespans than in the other parts of the world due to often limited access to healthcare. Over 50% of these patients die between 30 and 69 years of age, approximately ten years or more below the equivalent group in higher-income countries [45]. Consequently, death and disability attributable to CVD occur in the middle and economically productive age, affecting young families and the much-needed workforce in the region [45, 46]. Available evidence implicates stroke as the cause of the majority of CVD-related mortality in SSA [46]. With the absence of universal health coverage and robust health insurance systems among most SSA countries, patients and their families bear the costs of CVD care costs [47]. In some instances, patients forego treatment due to costs [47]. The impoverishing effect of out-of-pocket payments is increasingly pushing many individuals and families into poverty with family members affected by CVD [6].

5. Poverty, illiteracy, and indigenous knowledge system effect on CVD

Given the high cost and inaccessibility of biomedical care and medications for CVD, traditional healers are central to CVD treatment among patients in SSA [48, 49]. The spiritual underpinning of chronic diseases such as CVD, cultural beliefs, and taboos are reasons behind the preference of traditional healers over biomedicine as the first choice in some parts of SSA [50]. Consequently, it is not uncommon for individuals in the region to seek help from traditional healers to treat diabetes, hypertension, and stroke [51–53]. The belief that traditional healers are experts in treating and curing CVDs and their risk factors delays the transfer to biomedical care despite the clinical deterioration in some patients [50]. Those who transfer to biomedical care are less likely to maintain treatment compliance equivalent to traditional medicines. These culturally driven practices present the greatest threat to the treatment and control of CVDs and their risk factors [50]. Some cultural ideas partly explain the persistently low knowledge of CVDs, risk factors, and clinical symptoms in the SSA population [54]. Therefore, governments and other key stakeholder groups understanding these cultural-driven beliefs and practices are essential in devising strategies to improve health literacy in managing and controlling CVDs [55].

6. Effect of poverty on diagnosis treatment and control/eradication of CVD

With the growing burden of NCDs worldwide, the 2011 United Nation (UN) high-level meeting adopted a political declaration on NCDs that aimed at a 25% reduction in premature mortality from the four main NCDs (cardiovascular diseases, chronic respiratory diseases, cancers, and diabetes) by 25% relative to their 2010 levels by 2025 (the 25 × 25 target) [36]. In 2015, the UN SGD-3 was adopted to reduce by one-third premature mortality from NCDs by 2030 [17]. To realise

the SGD-3 target on health, a reduction in tobacco use, harmful alcohol use, salt intake, obesity, raised blood pressure, increased blood glucose and diabetes, and physical inactivity is essential [56]. Besides, treating people at high risk of CVD and ensuring a sustainable availability of medicines to treat NCDs and avoid potential complications is also critical [56]. The above measures are challenging to implement because of the regional poverty, underfunded healthcare systems and the absence of clear policies and strategies [57]. To overcome these challenges, governments and other key stakeholder groups need to instigate several measures that may reduce CVD morbidity and mortality, especially among the poor. These include researching to assess the optimal way to help diagnose CVD early and educate patients of the benefits of biomedical versus traditional medical approaches alongside lifestyle changes. In cognisance of the high levels of illiteracy among many of these patients, approaches such as pictograms are helpful in enhancing understanding [36, 58]. In addition, for governments to produce up-to-date guidelines that are robust and easy to use in electronic formats, with regular monitoring of prescribing patterns to improve the future quality of prescribing [59, 60]. This recognises that adherence to prescribing guidelines is seen as a better marker of the quality of prescribing than current WHO/INRUD criteria [61]. Alongside this, seek to instigate policies to enhance access to low-cost medicines, thereby reducing costly co-payments. This can potentially be achieved with the help of donors and pharmaceutical companies and exploring the potential for local manufacturing of multiple sourced medicines building on concerns during the COVID-19 pandemic [61]. In the meantime, exploration of the potential for aggressive procurement programmes since we have seen in Europe that such programmes have resulted in the prices of generic medicines used to manage CVD as low as 2% of pre-patent prices [62]. Issues of transport costs to clinics to effectively treat patients with CVD also needs to be researched further as lack of contact can be a significant barrier to adherence to medicines for NCDs [63]. In addition, exploring different methods to improve the convenience of medicine dispensing that reduces time off work building on current initiatives in South Africa and wider [27].

7. Conclusions

There are concerns about the rising burden of CVD in SSA, adding to the prevalent infectious diseases in the region. The increase in CVD is due to behavioural and metabolic risk factors resulting from the epidemiologic transition in the region. The intersection between poverty and CVD cuts through primordial, primary prevention and secondary prevention interventions. In the context of poverty in SSA, CVD prevention is a challenge due to competing demands to address the never conquered infectious diseases. With a weak healthcare system and out of pocket payment for the costs of CVD care, a significant proportion of individuals with CVD and their households are pushed into poverty. Besides, CVD affects a younger and productive population in SSA than in the rest of the world.

Consequently, CVD-related loss of productivity will push an additional number of individuals into poverty. Because of this, appropriate strategies are needed to address the rising burden of CVD across SSA, and these should include activities to address poverty issues. Activities include providing available funding and resources for effective screening for NCDs, especially CVD and diabetes, given high rates of patients not being diagnosed. Alongside this, improving the access and availability of medicines, especially where co-payments are an appreciable issue among patients. Multiple channels exist, including activities of donors as well as increasing local production. Alongside this, enhance educational input, especially

for patients with low educational levels, to improve adherence rates to suggested lifestyle changes and prescribed medicines, which can be appreciable concerns. This includes a more significant role for pharmacists and nurse practitioners in SSA ambulatory care clinics to help diagnose and manage CVDs. Access and other schemes can also help to enhance the affordability of chronic medications to prevent and manage CVDs, building on current schemes. Should there continue to be high poverty levels and lack of healthcare, including medicines, CVDs will continue to be a growing issue. This is not in the best interest of any key stakeholder group or higher income countries seeking to benefit from growing African populations. We will continue to monitor the situation.

Acknowledgements

There was no funding for this work.

Conflict of interest

The authors declare no conflict of interest.

Author details

Julius Chacha Mwita^{1*} and Brian Godman^{2,3}

1 University of Botswana, Gaborone, Botswana

2 Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, United Kingdom

3 School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

*Address all correspondence to: mwitajc@ub.ac.bw

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] World Health Organization. April 2, 2021]; Available from: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1.
- [2] World Health Organization regional committee for Africa. Noncommunicable Diseases. 2014 April 2, 2021]; Available from: <https://www.afro.who.int/health-topics/noncommunicable-diseases>.
- [3] Regional Committee for Africa. Cardiovascular diseases in the African region: current situation and perspectives: Report of the Regional Director. 2011 April 2, 2021]; Available from: <https://apps.who.int/iris/handle/10665/1871>.
- [4] Bigna, J.J. and J.J. Noubiap, The rising burden of non-communicable diseases in sub-Saharan Africa. *The Lancet Global Health*, 2019. 7(10): p. e1295-e1296. doi: 10.1016/S2214-109X(19)30370-5
- [5] Yuyun, M.F., et al., Cardiovascular Diseases in Sub-Saharan Africa Compared to High-Income Countries: An Epidemiological Perspective. *Glob Heart*, 2020. 15(1): p. 15. doi: 10.5334/gh.403
- [6] Salari, P., et al., The catastrophic and impoverishing effects of out-of-pocket healthcare payments in Kenya, 2018. *BMJ Glob Health*, 2019. 4(6): p. e001809. doi: 10.1136/bmjgh-2019-001809
- [7] Beaglehole, R. and R. Bonita, Global public health: a scorecard. *The Lancet*, 2008. 372(9654): p. 1988-1996.
- [8] United Nations - Department of Economic Social Affairs and Population Division. World population prospects 2019. 2019 [cited I: Comprehensive Tables ST/ESA/SER.A/426]; Available from: https://population.un.org/wpp/Publications/Files/WPP2019_Volume-I_Comprehensive-Tables.pdf.
- [9] World Bank Poverty and shared prosperity 2018: piecing together the poverty puzzle. 2018. <https://openknowledge.worldbank.org/bitstream/handle/10986/30418/9781464813306.pdf>.
- [10] World Bank. Year in Review: 2018 in 14 Charts. 2018 April 12, 2021]; Available from: <https://www.worldbank.org/en/news/feature/2018/12/21/year-in-review-2018-in-14-charts>.
- [11] World Bank Poverty and Shared Prosperity 2020: Reversals of Fortune. 2020. <https://openknowledge.worldbank.org/bitstream/handle/10986/34496/9781464816024.pdf>.
- [12] United Nations Development Programme and Oxford Poverty and Human Development Initiative. Global MPI 2020–Charting pathways out of multidimensional poverty: Achieving the SDGs. United Nations Development Programme (UNDP) and Oxford Poverty and Human Development Initiative (OPHI) 2020; Available from: <http://hdr.undp.org/en/2020-MPI>.
- [13] Williams, D. What are the Causes of Poverty. 2016; Available from: <https://borgenproject.org/what-causes-global-poverty/>.
- [14] Austin, G., African economic development and colonial legacies. 2010: Institut de hautes études internationales et du développement.
- [15] Kabuya, F.I., Fundamental causes of poverty in Sub-Saharan Africa. *IOSR Journal of Humanities and Social Science*, 2015. 20(6): p. 78-81.
- [16] Haacker, M., The economic consequences of HIV/AIDS in Southern Africa. 2002,

- [17] United Nations. Transforming our world: the 2030 Agenda for Sustainable Development. 2015 March 5, 2021]; Available from: <https://sustainabledevelopment.un.org/content/documents/21252030%20Agenda%20for%20Sustainable%20Development%20web.pdf>.
- [18] Chang, A.Y., et al., Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050. *The Lancet*, 2019. 393(10187): p. 2233-2260. doi: 10.1016/S0140-6736(19)30841-4
- [19] Addae-Korankye, A., Causes of poverty in Africa: A review of literature. *American International Journal of Social Science*, 2014. 3(7): p. 147-153.
- [20] Schultz, W.M., et al., Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. *Circulation*, 2018. 137(20): p. 2166-2178. doi: 10.1161/circulationaha.117.029652
- [21] Jones, C.A., et al., Cardiovascular disease risk among the poor and homeless - what we know so far. *Curr Cardiol Rev*, 2009. 5(1): p. 69-77. doi: 10.2174/157340309787048086
- [22] Mensah, G.A., et al., Mortality from cardiovascular diseases in sub-Saharan Africa, 1990-2013: a systematic analysis of data from the Global Burden of Disease Study 2013. *Cardiovascular journal of Africa*, 2015. 26(2 H3Africa Suppl): p. S6. doi: 10.5830/CVJA-2015-036
- [23] World Bank World development report 2000/2001: Attacking poverty. 2000. <http://documents1.worldbank.org/curated/en/230351468332946759/pdf/226840WDR00PUB0ng0pove rty0200002001.pdf>.
- [24] Murray, C.J., et al., The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary/edited by Christopher J. L. Murray, Alan D. Lopez. World Health Organization. 1996: World Health Organization.
- [25] Roth, G.A., et al., Global and regional patterns in cardiovascular mortality from 1990 to 2013. *Circulation*, 2015. 132(17): p. 1667-1678. doi: 10.1161/CIRCULATIONAHA.114.008720
- [26] Rosengren, A., et al., Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *The Lancet Global Health*, 2019. 7(6): p. e748-e760. doi: 10.1016/S2214-109X(19)30045-2
- [27] Meyer, J.C., et al., Ongoing initiatives to improve the quality and efficiency of medicine use within the public healthcare system in South Africa; a preliminary study. *Frontiers in pharmacology*, 2017. 8: p. 751.
- [28] Mwita, J.C., et al., Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. *BMJ open*, 2019. 9(7): p. e026807.
- [29] Asmelash, D. and Y. Asmelash, The Burden of Undiagnosed Diabetes Mellitus in Adult African Population: A Systematic Review and Meta-Analysis. *J Diabetes Res*, 2019. 2019: p. 4134937. doi: 10.1155/2019/4134937
- [30] Keates, A.K., et al., Cardiovascular disease in Africa: epidemiological profile and challenges. *Nature Reviews Cardiology*, 2017. 14(5): p. 273-293. doi: 10.1038/nrcardio.2017.19
- [31] Mwita, J.C., et al., Undiagnosed and diagnosed diabetes mellitus among

hospitalised acute heart failure patients in Botswana. *SAGE open medicine*, 2017. 5: p. 2050312117731473. doi: 10.1177/2050312117731473

[32] Godman, B., et al., Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. *Hospital practice*, 2020. 48(2): p. 51-67.

[33] Mwita, J.C., et al., Hypertension control and other cardiovascular risk factors among diabetic patients at Muhimbili National Hospital, Tanzania. *East African journal of public health*, 2013. 10(1): p. 337-342.

[34] Agyemang, C. and B.-J. van den Born, Limited access to CVD medicines in low-income and middle-income countries: poverty is at the heart of the matter. *The Lancet Global Health*, 2018. 6(3): p. e234-e235. doi: 10.1016/S2214-109X(18)30048-2

[35] Wekesah, F.M., et al., Understanding of and perceptions towards cardiovascular diseases and their risk factors: a qualitative study among residents of urban informal settings in Nairobi. *BMJ Open*, 2019. 9(6): p. e026852. doi: 10.1136/bmjopen-2018-026852

[36] Organization, W.H., Global NCD target: reduce premature deaths from NCDs. 2016, World Health Organization.

[37] Pazdernik, M., et al., Screening for RHD in Botswana: A young Czech team introduces echocardiography screening for rheumatic heart disease (RHD) in Botswana. 2019, Oxford University Press.

[38] Carapetis, J.R., et al., The global burden of group A streptococcal diseases. *Lancet Infect Dis*, 2005. 5(11): p. 685-694. doi: 10.1016/S1473-3099(05)70267-x

[39] Guilherme, L., J. Kalil, and M. Cunningham, Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. *Autoimmunity*, 2006. 39(1): p. 31-39. doi: 10.1080/08916930500484674

[40] Mayosi, B.M., et al., Rheumatic heart disease in Africa: the Mosi-o-Tunya call to action. *The Lancet Global Health*, 2014. 2(8): p. e438-e439. doi: 10.1016/S2214-109X(14)70234-7

[41] Coffey, P.M., A.P. Ralph, and V.L. Krause, The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review. *PLoS Negl Trop Dis*, 2018. 12(6): p. e0006577. doi: 10.1371/journal.pntd.0006577

[42] Karthikeyan, G. and B.M. Mayosi, Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? *Circulation*, 2009. 120(8): p. 709-713. doi: 10.1161/circulationaha.108.836510

[43] Günther, G., J. Asmera, and E. Parry, Death from rheumatic heart disease in rural Ethiopia. *Lancet*, 2006. 367(9508): p. 391. doi: 10.1016/S0140-6736(06)68128-2

[44] Remenyi, B., et al., Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. *Nature Reviews Cardiology*, 2013. 10(5): p. 284-292. doi: 10.1038/nrcardio.2013.34

[45] in Disease and Mortality in Sub-Saharan Africa, D.T. Jamison, et al., Editors. 2006, The International Bank for Reconstruction and Development/The World Bank Copyright © 2006, The International Bank for Reconstruction and Development/The World Bank.: Washington (DC).

[46] Moran, A., et al., The Epidemiology of Cardiovascular Diseases in

- Sub-Saharan Africa: The Global Burden of Diseases, Injuries and Risk Factors 2010 Study. *Progress in Cardiovascular Diseases*, 2013. 56(3): p. 234-239. doi: <https://doi.org/10.1016/j.pcad.2013.09.019>
- [47] Murphy, A., et al., The household economic burden of non-communicable diseases in 18 countries. *BMJ Glob Health*, 2020. 5(2): p. e002040. doi: 10.1136/bmjgh-2019-002040
- [48] Aikins, A.d.-G., Healer shopping in Africa: new evidence from rural-urban qualitative study of Ghanaian diabetes experiences. *BMJ*, 2005. 331(7519): p. 737. doi: 10.1136/bmj.331.7519.737
- [49] Winston, C.M. and V. Patel, Use of traditional and orthodox health services in urban Zimbabwe. *Int J Epidemiol*, 1995. 24(5): p. 1006-1012. doi: 10.1093/ije/24.5.1006
- [50] BeLue, R., et al., An overview of cardiovascular risk factor burden in sub-Saharan African countries: a socio-cultural perspective. *Globalization and Health*, 2009. 5(1): p. 10. doi: 10.1186/1744-8603-5-10
- [51] Lunyera, J., et al., Traditional medicine practices among community members with diabetes mellitus in Northern Tanzania: an ethnomedical survey. *BMC Complementary and Alternative Medicine*, 2016. 16(1): p. 282. doi: 10.1186/s12906-016-1262-2
- [52] Hughes, G.D., et al., The prevalence of traditional herbal medicine use among hypertensives living in South African communities. *BMC Complementary and Alternative Medicine*, 2013. 13(1): p. 38. doi: 10.1186/1472-6882-13-38
- [53] Bham, Z. and E. Ross, Traditional and western medicine: cultural beliefs and practices of South African Indian Muslims with regard to stroke. *Ethn Dis*, 2005. 15(4): p. 548-554.
- [54] Boateng, D., et al., Knowledge and awareness of and perception towards cardiovascular disease risk in sub-Saharan Africa: A systematic review. *PLoS One*, 2017. 12(12): p. e0189264. doi: 10.1371/journal.pone.0189264
- [55] Magnani, J.W., et al., Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association. *Circulation*, 2018. 138(2): p. e48-e74.
- [56] Kontis, V., et al., Contribution of six risk factors to achieving the 25× 25 non-communicable disease mortality reduction target: a modelling study. *The Lancet*, 2014. 384(9941): p. 427-437.
- [57] Nyaaba, G.N., et al., Tracing Africa's progress towards implementing the Non-Communicable Diseases Global action plan 2013-2020: a synthesis of WHO country profile reports. *BMC Public Health*, 2017. 17(1): p. 297. doi: 10.1186/s12889-017-4199-6
- [58] Sletvold, H., L.A.B. Sagmo, and E.A. Torheim, Impact of pictograms on medication adherence: A systematic literature review. *Patient education and counseling*, 2020. 103(6): p. 1095-1103.
- [59] Mashozhera, S., et al., Compliance to hypertensive prescribing guidelines and blood pressure control in elderly patients in Namibia: findings and implications. *Journal of Pharmaceutical Health Services Research*, 2021. 12(1): p. 53-60.
- [60] Niaz, Q., et al., Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. *International journal of clinical pharmacy*, 2020. 42: p. 1227-1236.
- [61] Niaz, Q., et al., Validity of World Health Organisation prescribing

indicators in Namibia's primary healthcare: findings and implications. *International journal for quality in health care*, 2019. 31(5): p. 338-345.

[62] Woerkom, M.v., et al., Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. *Journal of comparative effectiveness research*, 2012. 1(6): p. 527-538.

[63] Nashilongo, M., et al., Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. *Cardiovascular drugs and therapy*, 2017. 31(5): p. 565-578.